Healionics Corporation is a biomaterials company organized around addressng the needs of firm involved tissue regeneration and device biointegration. The firm offers sphere templated angiogenic regeneration (STAR) technology, which provides substrate independent, precision engineered, and 3D biomaterial scaffolds that enhance the bio-integration and promote healing of implanted medical devices. Haelionic's products are used in various areas, including wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, and urological/women's health. Healionics personnel are applying the firm's expertise in synthetic biomaterials to develop a novel vascular graft (artificial blood vessel) that, unlike existing grafts, remains open to blood flow long-term without need for costly interventions. The firm's first commercial application will be as a more reliable means of vascular access for dialysis patients, with a subsequent application to treat peripheral artery disease. Quality results have been achived in multiple controlled animal studies; the firm has a large patent portfolio; has established production capacity, and are ready to begin human studies in preparation for market launch
